PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of icmeSpringerOpen.comThis journalPublisherThis journalTOC AlertsSubmit onlineAims
 
Intensive Care Med Exp. 2015 December; 3(Suppl 1): A872.
Published online 2015 October 1. doi:  10.1186/2197-425X-3-S1-A872
PMCID: PMC4798159

Evaluation of chronic statin treatment on sepsis outcome in I.C.U

Severe sepsis and septic shock are common and frequently fatal problem in I.C.U. Recent therapeutic advances to routine clinical practice has proven controversial, because of their pleiotropic effects related to many pathophysiological determinants of sepsis. Statin therapy could be the next step in the search for adjuvant therapy. This study was done to evaluate chronic statin therapy on outcome of patients with sepsis and septic shock in I.C.U

Methods

We compared patients with severe sepsis and septic shock. Two groups were identified, group A, patients didn`t receive statin before or during their I.C.U management. Group B, patients with ongoing statin therapy before admission and continued during I.C.U therapy. The primary end point was the number of organ failure free days, hemodynamic failure free days and organ dysfunction free days up to day 14. Secondary endpoints included hospital mortality and safety.

Results

Patients in whom chronic statin therapy had been continued in the I.C.U (n = 45) had significantly more organ failure free days 12(5-15), organ dysfunction free days 10(2-13), hemodynamic failure free days 13(9-14) as compared to others non statin group(n = 33) with organ failure fee days 5(0-11), organ dysfunction free days 2(0-10), and hemodynamic failure free days 9(6-12). The need for increased mortality and hospital length of stay were comparable in the two groups.

Conclusions

Chronic statin therapy in I.C.U septic patients was associated with reduction in the severity of organ failure and hemodynamic failure with no improvement in hospital mortality and length of stay.

References

1. Casanouva MP, Pena JM, Rodroguez V, Ortega M. Severe sepsis and septic shock. Revista Espan Anestes. 2007;54(8):484–98. [PubMed]
2. Baignet C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, collins R, simes R, Cholesterol treatment Trialists'(CTT) collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90.056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1. [PubMed] [Cross Ref]
3. Mekontso-Dessap A, Brun-Buisson C. Statins: the next step in adjuvant therapy for sepsis? Intensive Care Med. 2006;32:11–14. doi: 10.1007/s00134-005-2860-5. [PubMed] [Cross Ref]
4. Jacobson JR. Statins in endothelial signaling and activation. Antioxid Redox signal. 2009;11:811–821. doi: 10.1089/ars.2008.2284. [PubMed] [Cross Ref]
5. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic reviewand meta-analysis. J Crit Care. 2010;25:656, e657–622. doi: 10.1016/j.jcrc.2010.02.013. [PubMed] [Cross Ref]

Articles from Intensive Care Medicine Experimental are provided here courtesy of Springer-Verlag